Ontology highlight
ABSTRACT:
INSTRUMENT(S): LTQ Orbitrap Elite, Q Exactive
ORGANISM(S): Homo Sapiens (human)
TISSUE(S): Brain, Epithelial Cell, Bone Marrow
DISEASE(S): Neuroblastoma
SUBMITTER: Vicky Yang
LAB HEAD: Bengt Hallberg
PROVIDER: PXD011187 | Pride | 2018-11-27
REPOSITORIES: Pride
Action | DRS | |||
---|---|---|---|---|
041216_24489_HG_tdra_q.mzXML | Mzxml | |||
041216_24489_HG_tdra_q.raw | Raw | |||
041216_24490_HG_tdra_q.mzXML | Mzxml | |||
041216_24490_HG_tdra_q.raw | Raw | |||
041216_24491_HG_tdra_q.mzXML | Mzxml |
Items per page: 1 - 5 of 74 |
Science signaling 20181120 557
Anaplastic lymphoma kinase (ALK) is a tyrosine kinase receptor that is a clinical target of major interest in cancer. Mutations and rearrangements in <i>ALK</i> trigger the activation of the encoded receptor and its downstream signaling pathways. <i>ALK</i> mutations have been identified in both familial and sporadic neuroblastoma cases as well as in 30 to 40% of relapses, which makes ALK a bona fide target in neuroblastoma therapy. Tyrosine kinase inhibitors (TKIs) that target ALK are currently ...[more]